UR-1505, a salicylate able to selectively block T-cell activation, shows intestinal anti-inflammatory activity in the chronic phase of the DSS model of rat colitis

Inflammatory Bowel Diseases

Volumn 14, Issue 7, 2008, Pages 888-897

  Bailón, Elvira ^a   Comalada, Mònica ^a   Román, Juan ^b   Michelena, Pedro ^b   Ramis, Isabel ^b   Merlos, Manuel ^b   Nieto, Ana ^c   Concha, Angel ^d   Zarzuelo, Antonio ^a   Gálvez, Julio ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b Palau Pharma SA   (Spain)

^c Health and Progress Foundation   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Innate immunity; Macrophages; NSAIDs; Rat DSS experimental colitis; Salicylates; T cells

Indexed keywords

2 HYDROXY 4 (2,2,3,3,3 PENTAFLUOROPROPOXY)BENZOIC ACID; CONCANAVALIN A; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DRINKING WATER; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; SALICYLIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UR 1505;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW; CHRONIC DISEASE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; EXPERIMENTAL MODEL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; CHRONIC DISEASE; COLITIS; DEXTRAN SULFATE; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, WISTAR; SALICYLIC ACIDS; T-LYMPHOCYTES;

EID: 47949089638     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20381     Document Type: Article

References (27)

1. Fiocchi C. Inflammatory bowel disease: aetiology and pathogenesis. Gastroenterology. 1998;115:182-205.
2. Neurath MF, Finotto S, Fuss I, et al. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 2001;22:21-26.
3. Holtmann MH, Galle PR, Neurath MF. Immunotherapeutic approaches to inflammatory bowel diseases. Expert Opin Biol Ther. 2001;1:455-466.
4. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
5. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004;126:1582-1592.
6. Matasic R, Dietz AB, Vuk-Pavlovic S. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology. 2000;101:53-60.
7. Paccani SR, Boncristiano M, Ulivieri C, et al. Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction. J Biol Chem. 2002;277:1509-1513.
8. Roman J, Fernandez de Arriba A, Barron S, et al. UR-1505, a new salicylate, blocks T cell activation through nuclear factor of activated T cells. Mol Pharmacol. 2007;72:269-279.
9. Bailon E, Camuesco D, Nieto A, et al. The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition. Biochem Pharmacol. 2007;74:1496-1506.
10. Kullmann F, Messmann H, Alt M, et al. Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats. Int J Colorectal Dis. 2001;16:238-246.
11. Fuss IJ, Marth T, Neurath MF, et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology. 1999;117:1078-1088.
12. Camuesco D, Comalada M, Rodriguez-Cabezas ME, et al. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol. 2004;143:908-918.
13. Dieleman LA, Ridwan BU, Tennyson GS, et al. Dextran sulphate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology. 1994;107:1643-1652.
14. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114:385-391.
15. Comalada M, Xaus J, Sanchez E, et al. Macrophage colony-stimulating factor-, granulocyte-macrophage colony-stimulating factor-, or IL-3-dependent survival of macrophages, but not proliferation, requires the expression of p21(Waf1) through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol. 2004;34:2257-2267.
16. Comalada M, Ballester I, Bailon E, et al. Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure-activity relationship. Biochem Pharmacol. 2006;72:1010-1021.
17. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344-1350.
18. Anderson ME. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 1985;113:548-555.
19. Comalada M, Camuesco D, Sierra S, et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits through down-regulation of the NF-kappaB pathway. Eur J Immunol. 2005;35:584-592.
20. Neurath MF, Fuss I, Schurmann G, et al. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci. 1998;859:149-159.
21. Panja A, Goldberg S, Eckmann L, et al. The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. J Immunol. 1998;161:3675-3684.
22. Xaus J, Comalada M, Valledor AF, et al. LPS induces apoptosis in macrophages mostly through the autocrine production of TNF-alpha. Blood. 2000;95:3823-3831.
23. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
24. Powrie F, Uhlig H. Animal models of intestinal inflammation: clues to the pathogenesis of inflammatory bowel disease. Novartis Found Symp. 2004;263:164-174.
25. Kwon KH, Murakami A, Hayashi R, et al. Interleukin-1 beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem Biophys Res Commun. 2005;337:647-654.
26. Neurath MF, Meyer zum Buschenfelde KH. Protective and pathogenic roles of cytokines in inflammatory bowel diseases. J Investig Med. 1996;44:516-521.
27. Shi D, Das J, Das G. Inflammatory bowel disease requires the interplay between innate and adaptive immune signals. Cell Res. 2006;16:70-74.